Base metrics
- Operating margin
- 7.1%
- Interest coverage
- 3.2x
- Return on equity (ROE)
- 3.8%
₩4,670-1.37%
2026-10-08 closePanGen Biotech's published financial data is dated 2026-10-04. 2024 revenue was KRW 14.67B. 2024 operating profit was KRW 1.05B.
Reported results
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 3.38
Distress
Grey
Safe
- Altman Z''
- 3.38
- Beneish M-Score
- -2.36
- Sloan accrual
- -6.69%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
9/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score9/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Operating margin −5pp
Interest coverage riskInterest coverageBase 3.2x adverse case 1x
Return on equity (ROE)Base 3.8% adverse case -0%
Revenue −15%
TolerableInterest coverageBase 3.2x adverse case 2.8x
Return on equity (ROE)Base 3.8% adverse case 2.3%
Interest rate +2pp
TolerableInterest coverageBase 3.2x adverse case 2.4x
Return on equity (ROE)Base 3.8% adverse case 2.5%
Interest coverage limit
Current margin 4.9ppInterest coverage limit at an operating margin of 2.2%
Interest expense coverage threshold
Quantus Signal · live data · not investment advice · Privacy Policy